<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id>
<journal-id journal-id-type="hwp">jbc</journal-id>
<journal-id journal-id-type="pmc">jbc</journal-id>
<journal-id journal-id-type="publisher-id">JBC</journal-id>
<journal-title-group>
<journal-title>The Journal of Biological Chemistry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9258</issn>
<issn pub-type="epub">1083-351X</issn>
<publisher>
<publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
<publisher-loc>11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110, U.S.A.</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28213518</article-id>
<article-id pub-id-type="pmc">5399111</article-id>
<article-id pub-id-type="publisher-id">M116.772541</article-id>
<article-id pub-id-type="doi">10.1074/jbc.M116.772541</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurobiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome</article-title>
<alt-title alt-title-type="short">GABA<sub>B</sub> receptors and fragile X syndrome</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kang</surname>
<given-names>Ji-Yong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chadchankar</surname>
<given-names>Jayashree</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vien</surname>
<given-names>Thuy N.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mighdoll</surname>
<given-names>Michelle I.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>§</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hyde</surname>
<given-names>Thomas M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>§</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>¶</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mather</surname>
<given-names>Robert J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>‖</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deeb</surname>
<given-names>Tarek Z.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pangalos</surname>
<given-names>Menelas N.</given-names>
</name>
<xref ref-type="aff" rid="aff5">**</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brandon</surname>
<given-names>Nicholas J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>‖</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dunlop</surname>
<given-names>John</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>‖</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moss</surname>
<given-names>Stephen J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>‖</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>‡‡</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1">From the <label>‡</label>AstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, Massachusetts 02111, </aff>
<aff id="aff2">the <label>§</label>Lieber Institute for Brain Development and </aff>
<aff id="aff3"><label>¶</label>Departments of Neurology and Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, </aff>
<aff id="aff4"><label>‖</label>Neuroscience, Innovative Medicines and Early Development, AstraZeneca, Waltham, Massachusetts 02451, </aff>
<aff id="aff5"><label>**</label>Innovative Medicines and Early Development, AstraZeneca, Melbourn Science Park, Cambridge Road, Royston Herts SG8 6EE, United Kingdom, and </aff>
<aff id="aff6">the <label>‡‡</label>Department of Neuroscience, Physiology and Pharmacology, University College, London WC1E 6BT, United Kingdom</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>1</label> To whom correspondence should be addressed: <addr-line>Dept. of Neuroscience, Tufts University School of Medicine, Boston, MA 02111.</addr-line> Tel.: <phone>617-636-3976</phone>; Fax: <fax>617-636-2413</fax>; E-mail: <email>Stephen.Moss@Tufts.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by F. Anne Stephenson</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>21</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>292</volume>
<issue>16</issue>
<fpage>6621</fpage>
<lpage>6632</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>7</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>The American Society for Biochemistry and Molecular Biology, Inc.</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="zbc01617006621.pdf"></self-uri>
<abstract>
<p>The behavioral and anatomical deficits seen in fragile X syndrome (FXS) are widely believed to result from imbalances in the relative strengths of excitatory and inhibitory neurotransmission. Although modified neuronal excitability is thought to be of significance, the contribution that alterations in GABAergic inhibition play in the pathophysiology of FXS are ill defined. Slow sustained neuronal inhibition is mediated by γ-aminobutyric acid type B (GABA<sub>B</sub>) receptors, which are heterodimeric G-protein-coupled receptors constructed from R1a and R2 or R1b and R2 subunits. Via the activation of G<sub>i/o</sub>, they limit cAMP accumulation, diminish neurotransmitter release, and induce neuronal hyperpolarization. Here we reveal that selective deficits in R1a subunit expression are seen in Fmr1 knock-out mice (KO) mice, a widely used animal model of FXS, but the levels of the respective mRNAs were unaffected. Similar trends of R1a expression were seen in a subset of FXS patients. GABA<sub>B</sub> receptors (GABA<sub>B</sub>Rs) exert powerful pre- and postsynaptic inhibitory effects on neurotransmission. R1a-containing GABA<sub>B</sub>Rs are believed to mediate presynaptic inhibition in principal neurons. In accordance with this result, deficits in the ability of GABA<sub>B</sub>Rs to suppress glutamate release were seen in Fmr1-KO mice. In contrast, the ability of GABA<sub>B</sub>Rs to suppress GABA release and induce postsynaptic hyperpolarization was unaffected. Significantly, this deficit contributes to the pathophysiology of FXS as the GABA<sub>B</sub>R agonist (<italic>R</italic>)-baclofen rescued the imbalances between excitatory and inhibitory neurotransmission evident in Fmr1-KO mice. Collectively, our results provided evidence that selective deficits in the activity of presynaptic GABA<sub>B</sub>Rs contribute to the pathophysiology of FXS.</p>
</abstract>
<kwd-group>
<kwd>GABA receptor</kwd>
<kwd>γ-aminobutyric acid (GABA)</kwd>
<kwd>inhibition mechanism</kwd>
<kwd>neurotransmitter receptor</kwd>
<kwd>synapse</kwd>
<kwd>fragile X</kwd>
<kwd>presynaptic</kwd>
</kwd-group>
<funding-group>
<award-group id="award1">
<funding-source>National Institute of Neurological Disorders and Stroke
<named-content content-type="funder-id">http://dx.doi.org/10.13039/100000065</named-content></funding-source>
<award-id>NS051195</award-id>
<award-id>NS056359</award-id>
<award-id>NS081735</award-id>
<award-id>R21NS080064</award-id>
<award-id>NS087662</award-id>
<award-id>MH097446</award-id>
</award-group>
<award-group id="award2">
<funding-source>U.S. Department of Defense
<named-content content-type="funder-id">http://dx.doi.org/10.13039/100000005</named-content></funding-source>
<award-id>AR140209</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>